Last reviewed · How we verify
TECHNETIUM TC-99M
Technetium Tc 99m Sestamibi accumulates in viable myocardial tissue, similar to thallous chloride TI-201, for scintigraphic imaging.
Technetium TC-99M is a marketed myocardial imaging agent that accumulates in viable myocardial tissue, similar to thallous chloride TI-201, for scintigraphic imaging. Its key strength lies in its well-established mechanism and widespread use in myocardial imaging, providing reliable diagnostic information. The primary risk is the key composition patent expiry in 2028, which could lead to increased competition from generic alternatives.
At a glance
| Generic name | TECHNETIUM TC-99M |
|---|---|
| Drug class | Radioactive Diagnostic Agent [EPC] |
| Modality | Small molecule |
| Phase | FDA-approved |
Mechanism of action
Technetium Tc 99m Sestamibi is a cationic complex that accumulates in living heart muscle tissue in a way similar to thallous chloride TI-201. This accumulation allows for the creation of scintigraphic images that can help identify both normal and diseased heart tissue.
Approved indications
- Myocardial Imaging
- Breast Imaging
Common side effects
- Body as a Whole
- Headache
- Cardiovascular
- Chest Pain/Angina
- ST Segment Changes
- Digestive System
- Nausea
- Special Senses
- Taste Perversion
- Parosmia
- Breast pain
Key clinical trials
- Testing the Safety of the Anti-cancer Drug, Sn-117m-DTPA, for Advanced Cancers That Have Spread to Bones (PHASE1)
- Repurposing Tilmanocept for Cardiac Sarcoidosis (PHASE2)
- SPECT/CT for the Characterization of Renal Masses
- Yttrium Y-90 Radioembolization in Treating Patients With Metastatic Liver Cancer (PHASE1)
- Tc99m Sestamibi Molecular Breast Imaging (NA)
- Comparative Analysis of Biotinylated, Irradiated and 51-Chromium Radiolabeled Red Blood Cells for Analysis of Recovery and Survival After Autologous Transfusion (PHASE1)
- Prospective Evaluation of Artificial Intelligence-enabled Screening for Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
- VSV-hIFNbeta-NIS With or Without Ruxolitinib Phosphate in Treating Stage IV or Recurrent Endometrial Cancer (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |